Dimerix

🧬 In our latest @DimerixLtd Deep Dive, we share our best secret fun facts. From child models & Opera House musicians, to rap and art fans - discover what makes us unique! Watch below 👇 #Dimerix #Biotech

@dimerixltd CEO & MD Dr Nina Webster will present at HealthInvest in Syd, Wed 3 Jun, hosted by @ir_department, @morgansAU, @StockheadAU & @AusBiotech. Dr Webster will share how $DXB is advancing DMX-200 to treat rare kidney disease #FSGS.🔗Register here: events.humanitix.com/healthinvest-j…

📹 @Dimerixltd ($DXB) CEO Dr Nina Webster sat down with @StockheadAU's @tylahtully to discuss the outcome of the blinded statistical review of our Phase 3 #ACTION3 trial in #FSGS, which was released last week. Watch the interview here: stockhead.com.au/stockhead-tv/l… #clinicaltrials

Great to see @dimerixltd’s ($DXB) announcement on the successful completion of the blinded analysis of our Phase 3 ACTION3 trial covered in @StockWirex. A clear explanation of how our strategy de-risks our regulatory approval pathway. stockwirex.com/asx-stock-news… #FSGS #kidneydisease

We’re pleased to share a short highlights video from $DXB's latest investor presentation, including an explanation of how the likelihood of a positive outcome with the ACTION3 trial has been substantially de‑risked. Watch the full video: youtu.be/Sj5qNVpd9zo #FSGS #ACTION3

@Dimerixltd today announces that it has successfully completed the blinded review of its Phase 3 ACTION3 trial, to confirm statistical assumptions for the primary endpoint. $DXB will pursue traditional approval for DMX-200. More here: investors.dimerix.com//investor-cent… #FSGS #ACTION3

Great to see @dimerixltd featured in Dr @timothyboreham's latest article in @StockheadAU, where he shares his take on pivotal upcoming milestones for ASX-listed biotechs, including $DXB's Phase 3 ACTION3 trial for #FSGS. Read here: stockhead.com.au/health/biocuri… #FSGS #kidneydisease

@PSR_Insights has published its latest report on @dimerixltd, pointing to a pivotal time ahead for $DXB with several important milestones and potential value drivers Read the full report here: investors.dimerix.com/investor-centr… #analystresearch #KidneyDisease #FSGS

Thank you to all who attended yesterday's investor briefing with @dimerixltd in Singapore. It was great to tell investors about our clinical and commercial strategy, including updates on our Phase 3 #FSGS trial. More info on $DXB: investors.dimerix.com/investor-centr… #FSGS #ACTION3

Thank you to @EurozHartleys for the updated research coverage on the FSGS landscape and its potential positive impact for Dimerix. Great news for FSGS patients who currently have limited treatment options. See a copy of the report here: investors.dimerix.com/investor-centr… #FSGS #proteinuria

This week, @dimerixltd ($DXB) CEO Dr Nina Webster and COO Dr Robert Shepherd presented at the Ignite Investment Summit in Hong Kong, to an audience of investors from top funds and institutions. Thank you to Ignite Partners for hosting. #igniteinvestmentsummit #APACinvesting

@dimerixltd (ASX:DXB) is pleased to confirm the location of our upcoming investor briefing in Singapore, Monday 20 April. The briefing will be held at the Fullerton Hotel, 1 Fullerton Square, starting at 12:30pm. Register here: investors.dimerix.com/investor-centr…  #investorbriefing

Great to see @dimerixltd featured in @StockheadAU's latest article from @morgansAU healthcare analyst Iain Wilkie, on his take on the biggest upcoming catalysts within the ASX biotech sector. Full article here: stockhead.com.au/health/morgans… #biotechinvesting #ASXBiotech

The latest research note from @EurozHartleys highlights that the recent tariff news from the US Administration will have no impact on @Dimerix ($DXB), given DMX-200 is manufactured in the US. Read the note here: investors.dimerix.com/investor-centr… #pharmaceuticaltariffs #analystresearch

@dimerixltd CEO Dr Nina Webster and COO Dr Robert Shepherd will be presenting at the Ignite partners’ Ignite Summit in Hong Kong (15-16 Apr) & Singapore (21-22 Apr). To book a meeting with $DXB at either summit, click here:  weareignite.com/investor/

This year's #WorldHealthDay theme is “Together for health. Standing with science”. At @dimerixltd, we know this is especially true for rare diseases. It takes inspiration, innovation & collaboration to develop new treatments for illnesses like FSGS. 🔗shorturl.at/MeUkO

@dimerixltd is delighted to be presenting at The World Congress of Nephrology 2026 in Japan this week. CMO Dr David Fuller will present on a retrospective study showing data supporting a proteinuria-based endpoint as a surrogate for kidney outcomes in FSGS theisn.org/wcn/

What’s your "Plan B" dream job? Our team’s "parallel universe" #careers are surprisingly creative! From floristry and interior design to wildlife conservation and even professional cricket,  our passions are diverse and these dreams fuel the #energy we bring to @dimerixltd

Kidneys are master filters, but inflammation is their enemy. This Kidney Awareness Month, @dimerixltd endorses the National Kidney Foundation's @nkf advice on managing factors that drive inflammation. More here: kidney.org/news-stories/n… #KidneyAwareness #FSGS #NationalKidneyMonth

Thanks to everyone who joined the @Dimerix investor briefing in Perth this week. It was a pleasure sharing our progress and outlook, and we greatly appreciated the strong engagement and discussion in the room.  We look forward to continuing the conversation! $DXB #ASX #Biotech